"10.1371_journal.pone.0080836","plos one","2014-01-13T00:00:00Z","Fariba Némati; Catherine de Montrion; Guillaume Lang; Laurence Kraus-Berthier; Guillaume Carita; Xavier Sastre-Garau; Aurélie Berniard; David Vallerand; Olivier Geneste; Ludmilla de Plater; Alain Pierré; Brian Lockhart; Laurence Desjardins; Sophie Piperno-Neumann; Stéphane Depil; Didier Decaudin","Laboratory of Preclinical Investigation, Department of Translational Research, Institut Curie, Paris, France; I.D.R.S., Institut de Recherches Servier, Croissy, France; I.R.I.S., Institut de Recherches International Servier, Suresnes, France; Department of Tumor Biology, Institut Curie, Paris, France; Department of Ophthalmological Oncology, Institut Curie, Paris, France; Department of Medical Oncology, Institut Curie, Paris, France","Conceived and designed the experiments: DD. Performed the experiments: FN CdM GL GC AB DV OG LdP. Analyzed the data: FN CdM LKB XS-G OG LD SPN SD DD. Contributed reagents/materials/analysis tools: AP BL. Wrote the paper: DD.","CdM, LKB, AP, BL, and SD belong to the Servier Laboratories which develop the new Bcl-2/Bcl-XL inhibitor S44563. This work was supported by a commercial source Servier Laboratories and one or more of the authors have an affiliation to the commercial funders of this research, Servier Laboratories. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","01","Fariba Némati","FN",16,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
